Patents by Inventor Egon Amann

Egon Amann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7220556
    Abstract: The cDNA which codes for factor XIIIa has been isolated using a cDNA bank from human placenta and probes constructed on the basis of the amino acid sequence of factor XIIIa peptide fragments. It is possible with this cDNA not only to obtain factor XIIIa by gene manipulation in high purity but also to prepare diagnostic aids which permit the analysis of genetic factor XIIIa defects. Furthermore, it is possible on the basis of the amino acid sequence to prepare antibodies which are suitable for diagnostic aids and antibody columns.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: May 22, 2007
    Assignee: ZLB Behring GmbH
    Inventors: Ulrich Grundmann, Egon Amann, Gerd Zettlmeissl
  • Patent number: 6869790
    Abstract: The cDNA which codes for factor XIIIa has been isolated using a cDNA bank from human placenta and probes constructed on the basis of the amino acid sequence of factor XIIIa peptide fragments. It is possible with this cDNA not only to obtain factor XIIIa by gene manipulation in high purity but also to prepare diagnostic aids which permit the analysis of genetic factor XIIIa defects. Furthermore, it is possible on the basis of the amino acid sequence to prepare antibodies which are suitable for diagnostic aids and antibody columns.
    Type: Grant
    Filed: March 12, 1993
    Date of Patent: March 22, 2005
    Assignee: Aventis Behring GmbH
    Inventors: Ulrich Grundmann, Egon Amann, Gerd Zettlmeissl
  • Patent number: 6746866
    Abstract: The cDNA which codes for factor XIIIa has been isolated using a cDNA bank from human placenta and probes constructed on the basis of the amino acid sequence of factor XIIIa peptide fragments. It is possible with this cDNA not only to obtain factor XIIIa by gene manipulation in high purity but also to prepare diagnostic aids which permit the analysis of genetic factor XIIIa defects. Furthermore, it is possible on the basis of the amino acid sequence to prepare antibodies which are suitable for diagnostic aids and antibody columns.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: June 8, 2004
    Assignee: Aventis Behring GmbH
    Inventors: Ulrich Grundmann, Egon Amann, Gerd Zettlmeissl
  • Patent number: 5869638
    Abstract: A bone-related protein named OSF-4 which is obtained from bone tissue of a mammal including mouse or human, and a process for its production. This protein is a novel naturally occurring mammal protein of the cadherin family.OSF-4 acts as an adhesion molecule or a growth factor which takes part in the process of osteogenesis at the site of bone induction. OSF-4 can be used as an agent for treating bone metabolic diseases, and its high organ specificity for bones enables its use as a diagnostic reagent for bone metabolic diseases.
    Type: Grant
    Filed: October 25, 1996
    Date of Patent: February 9, 1999
    Assignee: Hoechst Japan Limited
    Inventors: Sunao Takeshita, Makoto Okazaki, Shinji Kawai, Atsushi Tsujimura, Egon Amann
  • Patent number: 5756664
    Abstract: The present invention provides the sequence of the novel bone-related protein OSF-2 which can be obtained from mammalian bone tissues. The invention further provides a method of production of OSF-2 by recombinant techniques.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: May 26, 1998
    Assignee: Hoechst Japan Limited
    Inventors: Egon Amann, Yoko Otawara-Hamamoto, Reiko Kikuno, Sunao Takeshita, Kenichi Tezuka
  • Patent number: 5627050
    Abstract: A bone-related protein named OSF-8 which is obtained from bone tissue of a mammal including mouse or human, and a process for its production. This protein is a novel naturally occurring mammal protein which belongs to a group of sulfatases. OSF-8 degrades the sulfate groups of the sugar chains of proteoglycan, which makes up the cartilage matrix, during the replacement of cartilage into bone tissue at the stage of osteogenesis. OSF-8 can be used as an agent for treating bone metabolic diseases, and its high organ specificity for bones enables its use as a diagnostic reagent for bone metabolic diseases.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: May 6, 1997
    Assignee: Hoechst Japan Limited
    Inventors: Sunao Takeshita, Toshimi Ito, Yoko Otawara-Hamamoto, Egon Amann
  • Patent number: 5580758
    Abstract: The invention relates to a nucleic acid encoding a signal peptide from Bordetella pertussis, a recombinant molecule comprising the signal peptide, and processes for optimizing protein expression in Gram-negative bacteria employing the nucleic acid or signal peptide.
    Type: Grant
    Filed: February 7, 1995
    Date of Patent: December 3, 1996
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Stefan Knapp, Egon Amann, Karl-Josef Abel
  • Patent number: 5578708
    Abstract: Bone-associated proteins derived from bone of mammals, including mice and human beings, named OSF-6. The protein is the novel natural type mammal protein, which can play an important role in bone formation, and belongs to a group of transcription control factors.OSF-6 can be used as a therapeutic agent for bone metabolic diseases, and also as a diagnostic agent for bone metabolic diseases, since it may demonstrate a high organ specificity to bone.
    Type: Grant
    Filed: March 8, 1994
    Date of Patent: November 26, 1996
    Assignee: Hoechst Japan Limited
    Inventors: Makoto Okazaki, Sunao Takeshita, Shinji Kawai, Reiko Kikuno, Egon Amann
  • Patent number: 5460951
    Abstract: A bone-related carboxypeptidase-like protein named OSF-5 which is obtained from bone tissue of a mammal including mouse or human, and a process for its production. This protein is a novel naturally occurring mammal protein which belongs to a group of carboxypeptidase molecules.OSF-5 acts as an adhesion molecule or a growth factor which takes part in the process of osteogenesis at the site of bone induction. OSF-5 can be used as an agent for treating bone metabolic diseases, and its high organ specificity for bones enables its use as a diagnostic reagent for bone metabolic diseases.
    Type: Grant
    Filed: August 26, 1993
    Date of Patent: October 24, 1995
    Assignee: Hoechst Japan Limited
    Inventors: Shinji Kawai, Sunao Takeshita, Makoto Okazaki, Egon Amann
  • Patent number: 5320950
    Abstract: The protein PP4-X, whose amino acid sequence and the DNA sequence coding for this have been determined, has anticoagulative properties and can be prepared by genetic manipulation. PP4-X is used for therapeutic and diagnostic purposes.
    Type: Grant
    Filed: December 4, 1992
    Date of Patent: June 14, 1994
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Ulrich Grundmann, Karl-Josef Abel, Egon Amann
  • Patent number: 5202419
    Abstract: The protein PP4-X, whose amino acid sequence and the DNA sequence coding for this have been determined, has anticoagulative properties and can be prepared by genetic manipulation. PP4-X is used for therapeutic and diagnostic purposes.
    Type: Grant
    Filed: February 28, 1992
    Date of Patent: April 13, 1993
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Ulrich Grundmann, Karl-Josef Abel, Egon Amann
  • Patent number: 5159062
    Abstract: The invention relates to a new signal peptide from Bordetella pertussis with the amino acid sequence M K K W F V A A G I G A G L L M L S S A A and to particularly suitable expression vectors with whose aid such signal sequences can be found and/or evaluated.
    Type: Grant
    Filed: January 19, 1990
    Date of Patent: October 27, 1992
    Assignee: Behringwerde Aktiengesellschaft
    Inventors: Stefan Knapp, Egon Amann, Karl-Josef Abel